Pomegranate Extract May Boost Skin Health, Study Finds

A recent randomized, placebo-controlled trial suggests that Euromed’s Pomanox P30, a pomegranate extract, may support skin hydration and elasticity. The study, known as “Pomaskin”, also found reduced pigmentation from four weeks of use.

The extract is standardized to contain at least 30% punicalagins and is produced using Euromed’s proprietary water-based Pure-Hydro Process. Andrea Zangara, scientific communication advisor at Euromed, stated, “Pomaskin adds an exciting clinical dimension to the Pomanox P30 research program.”

Study Design and Key Findings

The trial involved 64 women aged 30–65 with hyperpigmented facial spots. Participants were administered either 367 mg or 700 mg of Pomanox P30 daily, or a placebo, for 12 weeks. The study was coordinated at the Nutrition and Health Unit of Eurecat in Reus, Spain.

Exploratory analyses of the 367 mg/day group showed positive results compared to the placebo. Skin hydration declined in the placebo group but was maintained in the Pomanox P30 group. Pigmentation changes were noticeable after four weeks, with a reduction in spot pigmentation. Favorable effects on the melanin index outside the spot persisted through week 12.

Hydration, Elasticity, and Microbiota

At 12 weeks, the 367 mg/day dose showed a significantly more pronounced hydration benefit than the placebo. Skin elasticity also improved, with significant changes observed at both four and 12 weeks for the 700 mg/day dose and at 12 weeks for the 367 mg/day dose.

The study also examined antioxidant-related parameters and polyphenol metabolism. The 367 mg/day group showed trends toward higher glutathione and superoxide dismutase levels. In the skin microbiota, nominal increases in Bifidobacterium and Lactobacillus were observed, coinciding with Pomanox P30 supplementation.

Future Research Directions

Levels of urinary polyphenol metabolites, including urolithin A glucuronide, increased in both Pomanox P30 groups, indicating absorption and metabolism of pomegranate compounds. The study’s microbiota analyses also pointed to potential research targets, with nominal increases in Prevotella and Akkermansia observed in the 367 mg/day group.

Euromed notes that while these findings suggest new directions for research into pomegranate polyphenols and the skin-gut relationship, effects on barrier function or inflammation have not yet been determined. The study provides a valuable basis for further clinical investigation and formulation development in beauty-from-within applications.